store at low temperature
store at -80°C
Glenzocimab (ACT017) is a Fab fragment of a humanized anti-GPVI monoclonal antibody. Glenzocimab demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model. Glenzocimab has been studied in acute ischemic stroke and cerebral thrombosis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 289.00 | |
5 mg | In stock | $ 696.00 | |
10 mg | In stock | $ 987.00 | |
25 mg | In stock | $ 1,490.00 | |
50 mg | In stock | $ 1,980.00 | |
100 mg | In stock | $ 2,720.00 |
Description | Glenzocimab (ACT017) is a Fab fragment of a humanized anti-GPVI monoclonal antibody. Glenzocimab demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model. Glenzocimab has been studied in acute ischemic stroke and cerebral thrombosis. |
Targets&IC50 | GPVI-Fc:1.37 μg/mL |
In vitro | Inhibited the binding of GPVI-Fc to collagen immobilized on microtiter plates, glenzocimab (0-100,000 ng/mL) demonstrated an IC50 of 1.37 μg/mL[2]. |
In vivo | Glenzocimab ( 1-8 mg / kg ; i.v. ) inhibited collagen-induced platelet aggregation in cynomolgus monkeys [ 2 ]. |
Synonyms | ACT017 |
Molecular Weight | N/A |
CAS No. | 2101829-58-5 |
store at low temperature
store at -80°C
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Glenzocimab 2101829-58-5 Others ACT017 ACT 017 ACT-017 inhibitor inhibit